Department of Experimental Research, State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou 510060, PR China.
J Immunother. 2012 Feb-Mar;35(2):189-95. doi: 10.1097/CJI.0b013e318241d9de.
In this study, we evaluate the efficacy of autologous cytokine-induced killer cells (CIK) transfusion used in combination with gemcitabine and cisplatin (GC) chemotherapy to treat nasopharyngeal carcinoma in patients with distant metastasis after radiotherapy. From September 2007 to August 2008, 60 patients with distant metastasis after radiotherapy were followed up and were randomly divided into 2 groups. The 30 patients in the GC+CIK group were treated with adoptive autologous CIK cell transfusion in combination with GC chemotherapy; the 30 patients in the GC group were treated with chemotherapy alone. Short-term efficacy evaluation revealed that in the GC+CIK group, there were 3 cases of complete remission, 18 cases of partial remission, 2 cases of stabilization of disease, and 7 cases of progression of disease and the total effective rate was 70% (21/30). In the GC group, there were 0 cases of complete remission, 14 cases of partial remission, 3 case of stable disease, and 13 cases of progressive disease and the total effective rate was 46.7% (14/21). Kaplan-Meier survival analysis showed that the overall survival of the GC+CIK group was higher than that of the GC group, but the difference was not significant (P=0.1374, log-rank test). However, the progression-free survival of the GC+CIK group was significantly higher than that of the GC group (P=0.0234, log-rank test). Thus, our study indicated that CIK cell transfusion therapy used in combination with GC chemotherapy may be a more effective treatment for postradiotherapy distant metastasis of nasopharyngeal carcinoma patients.
在这项研究中，我们评估了自体细胞因子诱导的杀伤细胞（CIK）输注联合吉西他滨和顺铂（GC）化疗治疗放射治疗后远处转移鼻咽癌患者的疗效。 2007 年 9 月至 2008 年 8 月，对 60 例放射治疗后远处转移的患者进行了随访，并随机分为 2 组。 GC+CIK 组 30 例患者接受过继自体 CIK 细胞输注联合 GC 化疗； GC 组 30 例患者接受单纯化疗。短期疗效评估显示，GC+CIK 组完全缓解 3 例，部分缓解 18 例，疾病稳定 2 例，疾病进展 7 例，总有效率为 70%（21/30）。在 GC 组中，完全缓解 0 例，部分缓解 14 例，稳定疾病 3 例，进展疾病 13 例，总有效率为 46.7%（14/21）。 Kaplan-Meier 生存分析显示，GC+CIK 组的总生存率高于 GC 组，但差异无统计学意义（P=0.1374，对数秩检验）。然而，GC+CIK 组的无进展生存率明显高于 GC 组（P=0.0234，对数秩检验）。因此，我们的研究表明，CIK 细胞输注联合 GC 化疗可能是一种更有效的治疗放射治疗后鼻咽癌远处转移的方法。
